← All trials
NCT00910728
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2009
- Primary completion
- Mar 1, 2012
- Completion date
- Aug 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 65
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- AstraZenecaLead sponsor
- Icahn School of Medicine at Mount SinaiOverall official - principal investigator
- AstraZenecaStudy director
- Institut Gustave RoussyOverall official - principal investigator
- Institut Gustave RoussyCollaborator
- University of Texas at HoustonOverall official - principal investigator
- The University of Texas, DallasCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.